Neutropenia Treatment Market by Treatment (Colony-stimulating factors, Antibiotics, Antifungals, and Antivirals), and Distribution Channel (Hospital Pharmacies , Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 20202027
- Published Date: 2020-11-18
- Report ID: 18227
- Pages: 210
-
Format:
The global neutropenia treatment market was valued at $12,602.5 million in 2019, and is expected to reach $19,303.1 million by 2027, with a CAGR of 5.4% during the forecast period.
Neutropenia refers to reduced neutrophil count in the blood. Normal individuals have a neutrophil count in the blood ranging between 1,500 and 8,000 cells/cubic meter. When neutrophil count falls below the 1,500 cells/mm3 threshold, a patient is classified as neutropenic. Generally, neutrophils drop below normal level within after 7-12 days of cancer chemotherapy.
The demand for neutropenia therapy is projected to experience substantial growth in the future, owing to growth in incidences of cancer cases. Increase in R&D activities by key companies to establish new neutropenia therapies are also anticipated to fuel the demand during the forecast period. However, high cost of neutropenia care and strict drug approval rules and regulations are likely to hinder the market growth during the forecast period. In addition, paradigm transition from branded drugs to low-cost biosimilars is projected to provide industry players with remunerative incentives.
Depending on treatment, the market is categorized into colony-stimulating factors, antibiotics, antifungals, and antivirals. The colony-stimulating factors segment dominated the global market in 2019, and is anticipated to continue this trend during the forecast period. Rise in incidences of cancer cases and further increase in number of patients undergoing chemotherapy around the globe drives the growth of this treatment segment.
On the basis of distribution channel, the market is categorized into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment held a dominant portion in the market, accounting for about 40.6% share of the global neutropenia treatment market in 2019.
North America accounted for the largest share in the global neutropenia treatment market. Further, Asia-Pacific is expected to witness highest growth rate for the market throughout the forecast period. Increase in incidences of leukemia will drive the overall market during the forecast period. As, Europe is considered as the advanced biosimilar market as compared to non-European countries, high cost of the treatment of neutropenia is expected to restrict the growth of the market during the forecast period.
The major companies profiled in this report include Amgen, BeyondSpring, Kyowa Kirin, Cellerant Therapeutics, Mylan N.V., Novartis AG, Partner Therapeutics, Pfizer, Spectrum Pharmaceuticals and Teva Pharmaceutical Industries Ltd. Other players in neutropenia market (not profiled in the report) include Myelo Therapeutics, and Enzychem Lifesciences Corporation Samsung Medical Center.
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis along with the current neutropenia treatment trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
The market forecast is studied from 2020 to 2027.
The market size and estimations are based on a comprehensive analysis of key developments in the industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Treatment
Colony-stimulating factors,
Antibiotics
Antifungals
Antivirals
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o UK
o Germany
o France
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o Rest of Asia-Pacific
LAMEA
o Brazil
o South Africa
o Saudi Arabia
o Rest of LAMEA
KEY MARKET PLAYERS
Amgen
BeyondSpring
Kyowa Kirin
Cellerant Therapeutics
Mylan N.V.
Novartis AG
Partner Therapeutics
Pfizer
Spectrum Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
Coherus Biosciences
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Pipeline Analysis
3.2.2.Top winning strategies
3.2.3.Top player positioning
3.3.Key forces shaping the global neutropenia treatment market
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Rise in prevalence of leukemia
3.4.1.2.Surge in R&D efforts and development of new drugs
3.4.1.3.Fundamental shift from branded drugs to biosimilars in cancer supportive treatment
3.4.2.Restraints
3.4.2.1.High cost of the treatment of neutropenia
3.4.2.2.Stringent rules and regulations for product approvals
3.4.3.Opportunity
3.4.3.1.Robust drug pipeline for neutropenia treatment
3.5.Standard of Care for Neutropenia treatment and recommended guidelines
CHAPTER 4:GLOBAL NEUTROPENIA TREATMENT MARKET, BY TREATMENT
4.1.Overview
4.1.1.Market size and forecast
4.2.Colony-stimulating factors (CSFs)
4.2.1.Key market trends, growth factors and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Antibiotics
4.3.1.Key market trends, growth factors and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Antifungals
4.4.1.Key market trends, growth factors and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Antivirals
4.5.1.Key market trends, growth factors and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:GLOBAL NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
5.1.Overview
5.1.1.Market size and forecast
5.2.Hospital Pharmacies
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Retail Pharmacies
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Online Pharmacies
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
CHAPTER 6:GLOBAL NEUTROPENIA TREATMENT MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends and opportunities
6.2.2.Market size and forecast, by treatment
6.2.3.Market size and forecast, by distribution channel
6.2.4.Market size and forecast, by country
6.2.4.1.U.S.
6.2.4.2.Purchasing/distribution channels in the U.S.
6.2.4.2.1.U.S. market size and forecast, by treatment
6.2.4.2.2.U.S. market size and forecast, by distribution channel
6.2.4.3.Canada
6.2.4.3.1.Canada market size and forecast, by treatment
6.2.4.3.2.Canada market size and forecast, by distribution channel
6.2.4.4.Mexico
6.2.4.4.1.Mexico market size and forecast, by treatment
6.2.4.4.2.Mexico market size and forecast, by distribution channel
6.3.Europe
6.3.1.Key market trends and opportunities
6.3.2.Market size and forecast, by treatment
6.3.3.Market size and forecast, by distribution channel
6.3.4.Market size and forecast, by country
6.3.4.1.Purchasing/distribution channels in the Europe
6.3.4.2.Germany
6.3.4.2.1.Germany market size and forecast, by treatment
6.3.4.2.2.Germany market size and forecast, by distribution channel
6.3.4.3.France
6.3.4.3.1.France market size and forecast, by treatment
6.3.4.3.2.France market size and forecast, by distribution channel
6.3.4.4.UK
6.3.4.4.1.UK market size and forecast, by treatment
6.3.4.4.2.UK market size and forecast, by distribution channel
6.3.4.5.Italy
6.3.4.5.1.Italy market size and forecast, by treatment
6.3.4.5.2.Italy market size and forecast, by distribution channel
6.3.4.6.Spain
6.3.4.6.1.Spain market size and forecast, by treatment
6.3.4.6.2.Spain market size and forecast, by distribution channel
6.3.4.7.Rest of Europe
6.3.4.7.1.Rest of Europe market size and forecast, by treatment
6.3.4.7.2.Rest of Europe market size and forecast, by distribution channel
6.4.Asia-Pacific
6.4.1.Key market trends and opportunities
6.4.2.Market size and forecast, by treatment
6.4.3.Market size and forecast, by distribution channel
6.4.4.Market size and forecast, by country
6.4.4.1.Japan
6.4.4.1.1.Purchasing/distribution channels in the Japan
6.4.4.1.2.Japan market size and forecast, by treatment
6.4.4.1.3.Japan market size and forecast, by distribution channel
6.4.4.2.China
6.4.4.2.1.China market size and forecast, by treatment
6.4.4.2.2.China market size and forecast, by distribution channel
6.4.4.3.Australia
6.4.4.3.1.Australia market size and forecast, by treatment
6.4.4.3.2.Australia market size and forecast, by distribution channel
6.4.4.4.India
6.4.4.4.1.India market size and forecast, by treatment
6.4.4.4.2.India market size and forecast, by distribution channel
6.4.4.5.Rest of Asia-Pacific
6.4.4.5.1.Rest of Asia-Pacific market size and forecast, by treatment
6.4.4.5.2.Rest of Asia-Pacific market size and forecast, by distribution channel
6.5.LAMEA
6.5.1.Key market trends and opportunities
6.5.2.Market size and forecast, by treatment
6.5.3.Market size and forecast, by distribution channel
6.5.4.Market size and forecast, by country
6.5.4.1.Brazil
6.5.4.1.1.Brazil market size and forecast, by treatment
6.5.4.1.2.Brazil market size and forecast, by distribution channel
6.5.4.2.Saudi Arabia
6.5.4.2.1.Saudi Arabia market size and forecast, by treatment
6.5.4.2.2.Saudi Arabia market size and forecast, by distribution channel
6.5.4.3.South Africa
6.5.4.3.1.South Africa market size and forecast, by treatment
6.5.4.3.2.South Africa market size and forecast, by distribution channel
6.5.4.4.Rest of LAMEA
6.5.4.4.1.Rest of LAMEA market size and forecast, by treatment
6.5.4.4.2.Rest of LAMEA market size and forecast, by distribution channel
CHAPTER 7:COMPANY PROFILES
7.1.AMGEN INC.
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.BEYONDSPRING INC.
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Product portfolio
7.2.4.Business performance
7.2.5.Key strategic moves and developments
7.3.CELLERANT THERAPEUTICS, INC.
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Product portfolio
7.3.4.Key strategic moves and developments
7.4.KYOWA KIRIN
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.5.MYLAN N.V.
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.NOVARTIS AG
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.7.PARTNER THERAPEUTICS, INC.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Product portfolio
7.7.4.Key strategic moves and developments
7.8.PFIZER INC.
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.SPECTRUM PHARMACEUTICALS, INC.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.11.COHERUS BIOSCIENCES, INC.
7.11.1.Company overview
7.11.2.Company snapshot
7.11.3.Operating business segments
7.11.4.Product portfolio
7.11.5.Business performance
7.11.6.Key strategic moves and developments
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
